Cargando…
Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
Bone marrow transplantation (BMT) was introduced as a treatment option 15 years ago for severe, drug-resistant multiple sclerosis (MS). Up until now, BMT has been undertaken in relatively few patients worldwide, with moderate success, and recent studies suggest that patients with early, highly aggre...
Autores principales: | Mouzaki, Athanasia, Koutsokera, Maria, Dervilli, Zoe, Rodi, Maria, Kalavrizioti, Dimitra, Dimisianos, Nikolaos, Matsoukas, Ioannis, Papathanasopoulos, Panagiotis |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962327/ https://www.ncbi.nlm.nih.gov/pubmed/21042570 http://dx.doi.org/10.2147/IJGM.S13648 |
Ejemplares similares
-
Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis
por: Dimisianos, Nikolaos, et al.
Publicado: (2014) -
Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens
por: Rodi, Maria, et al.
Publicado: (2016) -
Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation
por: Mouzaki, Athanasia, et al.
Publicado: (2015) -
Correction: Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation
por: Mouzaki, Athanasia, et al.
Publicado: (2016) -
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)